Head to head
Enlicitide against Simvastatin
An oral PCSK9 inhibitor against the statin most people are given. Enlicitide cut LDL cholesterol by 57 percent in 2,909 people, which is a lipid number; simvastatin cut all-cause mortality from 14.7 to 12.9 percent over five years in 20,536 high risk adults, which is an outcome. Those are different kinds of evidence and the gap between them is the point of this page.
Column A
EnlicitideEnlicitide decanoate (oral macrocyclic peptide PCSK9 inhibitor)
The first PCSK9 inhibitor you can swallow. A macrocyclic peptide that cut LDL cholesterol by 57 percent in 2,909 people, in a class that until now required injection.
Column B
SimvastatinSimvastatin, HMG-CoA reductase inhibitor
Fed to mice at 12 and 120 ppm from 9 months of age, simvastatin had no effect on survival in either sex. In 20,536 high-risk adults it cut all-cause mortality from 14.7 percent to 12.9 percent over five years. Both results are real and they answer different questions.
Side by side, on the facts we can check
| Attribute | Enlicitide | Simvastatin |
|---|---|---|
| Category | Metabolic | Longevity |
| FDA status | FDA approved 2026 for lowering LDL cholesterol. Prescription only. | Approved and in wide use for hyperlipidaemia and cardiovascular risk reduction. No approval and no indication relating to ageing or lifespan. |
| Half-life | Effective half-life around 14 hours; terminal half-life considerably longer | About 2 hours for the parent drug, though the effect on cholesterol synthesis outlasts plasma exposure, which is why it is dosed once daily. |
| Molecular weight | Approximately 1,722 Da | 418.6 Da. A small molecule, not a peptide. |
| Mechanism | Binds PCSK9 and blocks it from binding the LDL receptor. PCSK9 normally marks LDL receptors for destruction, so inhibiting it leaves more receptors on the liver surface to clear LDL from the blood. The oral delivery relies on a macrocyclic structure resistant to gut proteases, combined with an absorption enhancer. | A competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme of the mevalonate pathway, which lowers hepatic cholesterol synthesis and upregulates LDL receptors, clearing LDL from plasma. The same pathway produces isoprenoids used to prenylate small GTPases, which is the basis of the so-called pleiotropic effects, including reduced vascular inflammation, and also the most likely basis of statin-associated muscle symptoms. The geroscience hypothesis rested on those pleiotropic effects rather than on cholesterol lowering, since laboratory mice do not develop the atherosclerosis that statins prevent in people. |
| Human studies cited | 3 | 2 |
| Legal status, US | Prescription only; FDA approved | FDA-approved, prescription only |
Frequently asked questions
What is the difference between Enlicitide and Simvastatin?
Enlicitide: The first PCSK9 inhibitor you can swallow. A macrocyclic peptide that cut LDL cholesterol by 57 percent in 2,909 people, in a class that until now required injection. Simvastatin: Fed to mice at 12 and 120 ppm from 9 months of age, simvastatin had no effect on survival in either sex. In 20,536 high-risk adults it cut all-cause mortality from 14.7 percent to 12.9 percent over five years. Both results are real and they answer different questions.
Which has stronger research evidence, Enlicitide or Simvastatin?
This database does not grade compounds. It counts what was run in people: 3 of the 3 studies cited on the Enlicitide profile were human work, against 2 of 3 for Simvastatin. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.
Are Enlicitide and Simvastatin FDA-approved?
Enlicitide: FDA approved 2026 for lowering LDL cholesterol. Prescription only.. Simvastatin: Approved and in wide use for hyperlipidaemia and cardiovascular risk reduction. No approval and no indication relating to ageing or lifespan..
Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.